L-Alanosine

N/A

Report date: 2023/04/21 17:47:05
NME

Base Information

Drug NameL-Alanosine
Drug Alias Name阿拉诺新SDX-102NSC-153353
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionAdenylosuccinate synthetase 2 inhibitors
TargetsAdenylosuccinate synthetase 2
Therapy Area/IndicationsCNS Embryonal TumorLung NeoplasmsCentral Nervous System Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of CaliforniaNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of CaliforniaNational Cancer InstituteTeva Pharmaceutical Industries Ltd
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorLung NeoplasmsCentral Nervous System Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A